Spero Therapeutics, Inc.
SPRO
$0.71
-$0.0152-2.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 11.69% | 32.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.69% | 32.09% | |||
| Cost of Revenue | 13,059.46% | -97.04% | |||
| Gross Profit | -588.98% | 194.37% | |||
| SG&A Expenses | 35.74% | -6.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.95% | 9.58% | |||
| Operating Income | -12.13% | 2.46% | |||
| Income Before Tax | -18.13% | 2.38% | |||
| Income Tax Expenses | 200.00% | -- | |||
| Earnings from Continuing Operations | -21.82% | 4.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.82% | 4.00% | |||
| EBIT | -12.13% | 2.46% | |||
| EBITDA | -12.13% | 2.45% | |||
| EPS Basic | -20.90% | 4.29% | |||
| Normalized Basic EPS | -12.21% | 2.66% | |||
| EPS Diluted | -21.24% | 4.29% | |||
| Normalized Diluted EPS | -12.21% | 2.66% | |||
| Average Basic Shares Outstanding | 0.76% | 0.31% | |||
| Average Diluted Shares Outstanding | 0.76% | 0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||